Today: 12 March 2026
Subscribe
Browse Category

NYSE:GSK 11 November 2025 - 17 December 2025

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

The FDA approved GSK’s Exdensur (depemokimab-ulaa) on Dec. 17 as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and older. Phase III trials showed up to 58% fewer annual asthma exacerbations versus placebo. The FDA declined approval for a second indication, chronic rhinosinusitis with nasal polyps. GSK faces a leadership change Jan. 1, 2026.
17 December 2025
··
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK faces a key FDA decision on depemokimab for severe asthma and nasal polyps on Dec. 16, following recent EU regulatory backing for the drug and other respiratory products. GSK ADRs last traded at $48.81, while London shares opened at 1,816.50p. Analysts are watching for potential shifts in revenue forecasts and valuation as regulatory outcomes approach.
15 December 2025
··
GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK shares traded near $48.88 Friday as the company reported key regulatory wins. The EMA’s CHMP backed expanding Arexvy’s RSV vaccine to all adults 18+ in Europe, with a final decision expected in February. The FDA also approved Blujepa (gepotidacin) for gonorrhea, marking the first new antibiotic class for the infection in decades. Analyst consensus sees Arexvy sales rising to £1.17 billion by 2031.
12 December 2025
··
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

The US FDA granted Orphan Drug Designation to GSK’s experimental lung cancer therapy risvutatug rezetecan on December 10. GSK shares traded near 1,780 pence in London, up about 29% over 12 months. The drug targets small-cell lung cancer and has shown durable responses in early trials. GSK’s US ADR closed at $47.27, near its 52-week high.
10 December 2025
···
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK shares traded near 52-week highs on December 9, 2025, with London shares at £18.05 and NYSE ADRs at $48.5, both up over 30% year-on-year. The stock surged after a Q3 earnings beat and upgraded 2025 guidance, driven by strong HIV and oncology drug sales. GSK now expects full-year sales growth of 6–7% and core EPS growth of 10–12%.
9 December 2025
···
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK shares traded near multi-year highs on 4 December, closing at 1,826–1,837p in London and $48.57 in New York, up over 40% year-to-date. The company repurchased more than 11.5 million shares since late September as part of a £2 billion buyback. New executive share options were granted on 5 December. Market cap stands at about £73 billion in London and just under $100 billion in New York.
5 December 2025
··
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK closed near 1,783p in London on 2 December 2025, just below its 52-week high, after strong Q2 and Q3 results lifted shares nearly 40% over 12 months. Q3 sales rose 8% at constant exchange to £8.5 billion, with oncology up 39% and core EPS up 14%. The ADR ended at $47.19 in New York. Analyst focus remains on the company’s growth pipeline and 2031 revenue targets.
2 December 2025
····
GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK shares closed at $47.9 on November 28, just below a 52-week high, after a year-to-date gain of about 30–40%. The company beat earnings expectations in Q2 and Q3, raised full-year guidance, and saw its cancer drug Blenrep re-approved in major markets. CEO Emma Walmsley will step down December 31, with Luke Miels to take over January 1. Most analysts rate the stock a “Hold” despite recent outperformance.
1 December 2025
··
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

GSK shares closed up 0.23% at 1,776p in London on Thursday, trading between 1,772p and 1,790p on light volume. Jefferies raised its target price to 2,100p and reiterated a “Buy” rating. Recent R&D announcements and a new oncology collaboration with LTZ Therapeutics continued to influence sentiment. Over the past year, GSK shares have gained about 36%.
20 November 2025
··
1 2

Stock Market Today

  • Stock Market Crash March 12, 2026: Nifty50 Drops Below 23,600 Amid US-Iran War
    March 12, 2026, 12:35 AM EDT. The Indian stock market opened sharply lower on March 12, 2026, with Nifty50 falling below 23,600 and the BSE Sensex dropping over 900 points, driven by escalating tensions in the US-Iran war. Brent crude oil prices surged past $100, intensifying market volatility. Foreign portfolio investors sold shares worth Rs 6,267 crore, outpacing domestic institutional buying of Rs 4,966 crore. Analysts warn that continued geopolitical conflict and crude price fluctuations are likely to keep markets unstable. Experts advise investors to remain calm, maintain systematic investment plans, and consider accumulating quality bluechip stocks amid market weakness.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 12.03.2026

12 March 2026
LIVEMarkets rolling coverageStarted: March 12, 2026, 12:00 AM EDTUpdated: March 12, 2026, 12:35 AM EDT Stock Market Crash March 12, 2026: Nifty50 Drops Below 23,600 Amid US-Iran War March 12, 2026, 12:35 AM EDT. The Indian stock market opened sharply lower on March 12, 2026, with **Nifty50 falling below 23,600** and the **BSE Sensex dropping over 900 points**, driven by escalating tensions in the **US-Iran war**. Brent crude oil prices surged past $100, intensifying market volatility. Foreign portfolio investors sold shares worth Rs 6,267 crore, outpacing domestic institutional buying of Rs 4,966 crore. Analysts warn that continued geopolitical conflict and
XRP Price Today: Ripple’s Australia License Push Keeps XRP Near $1.40

XRP Price Today: Ripple’s Australia License Push Keeps XRP Near $1.40

11 March 2026
XRP traded near $1.40, down 1.4% Wednesday, after Ripple announced plans to acquire BC Payments Australia to secure an Australian Financial Services Licence. The move comes as Australia tightens licensing rules for digital-asset firms. Broader crypto markets remained cautious amid concerns over oil prices, Iran, and U.S. inflation. Ripple’s deal is pending completion.
Natural Gas Price Today: Europe Gas Holds Firm as Brussels Weighs Cap After Qatar Shock

Natural Gas Price Today: Europe Gas Holds Firm as Brussels Weighs Cap After Qatar Shock

11 March 2026
European natural gas prices held near 48 euros per megawatt hour Wednesday as Shell declared force majeure on Qatari LNG cargoes, with disruptions expected to hit from April. Asia is bidding up for replacement fuel, while Brussels considers subsidies or a price cap. LNG Canada increased shipments, but analysts warn Europe’s gas storage could end March far below average if Qatari supply issues persist.
Go toTop